A few stocks from ASX listed companies despite falling have been able to their sheen. Two such stocks of potential growth companies are
Alpha HPA Limited (ASX: A4N)
Alpha HPA Limited (ASX: A4N) is making significant progress in the development of its sapphire and high purity alumina (HPA) projects. The company’s sapphire marketing efforts, initiated in May 2024, have focused on key sectors including optics, LED technology, and semiconductor applications. Alpha Sapphire has seen accelerated adoption of GaN-on-sapphire semiconductors, driven by demand from large semiconductor companies developing high-power, high-frequency devices. This unexpected demand has positively impacted Alpha’s business, alongside the launch of sapphire optics and the supply of 8-inch sapphire boules for semiconductor end-users. However, the commercial scale adoption of wide-format sapphire for microLED technology has been delayed.
Alpha’s HPA projects are also advancing steadily. Among the best growth stocks to buy now, it has made notable progress in Stage 1 of its HPA production, with solvent extraction and Al-Nitrate circuits now operating at steady state and an inventory exceeding 15 metric tonnes, including sintered HPA tablets. Stage 2 is moving forward with earthworks on schedule and key engineering layouts in development. Alpha’s marketing in the Direct Lithium Extraction (DLE) sector has been particularly successful, as its high-purity alumina tri-hydrate (ATH) materials have outperformed competitors’ sorbents in lithium extraction tests. Demand for Alpha’s ATH granules, used in DLE, continues to grow as the company engages with key players in the energy and materials sectors.
In addition, Alpha has made strides in the semiconductor sector, where its HPA materials are now being used for thermal interface materials in semiconductor packaging. Sales have been building steadily, with recent orders and positive feedback from end-users. Moreover, Alpha has expanded its capabilities to coat Li-ion battery cells with an Al-Nitrate-based coating to prevent thermal runaway, addressing increasing concerns in the EV and stationary storage sectors. This fire-safety technology, combined with the company’s ongoing production capacity expansion, positions Alpha for continued growth in these high-demand markets.
Microba Lifesciences Limited (ASX: MAP)
Microba Lifesciences Limited (ASX: MAP) has made remarkable strides across its operations this year, highlighted by robust growth in its MetaXplore and MetaPanel diagnostic testing platforms. In Australia, MetaXplore sales have nearly doubled year-on-year, with Q2 sales pointing to an annualized run rate exceeding 11,000 tests. This growth is driven by increasing adoption by clinicians, proactive sales campaigns, and targeted education initiatives. With five weeks remaining in the half, sales momentum remains strong, significantly outpacing the previous period. MetaPanel has also reached a key milestone of 500 tests sold since its launch. Clinician feedback underscores its utility in detecting pathogens often missed by standard diagnostics, leading to effective patient outcomes. Ongoing national education programs and marketing efforts are expected to drive further adoption, with additional clinical studies and publications set to enhance its credibility. This marks a significant shift in pathogen testing, introducing a new diagnostic category that challenges the status quo since the advent of PCR in the 1990s. Internationally, the UK market is showing promising early results following Microba’s acquisition of Invivo Clinical. The local team has been strengthened with seasoned professionals, including Alaster Stockwell Jones, and the first MetaXplore tests have been sold, processed, and delivered. Market access will expand progressively in 2025, with early traction signaling a solid growth trajectory.
Zooming out, Microba’s progress aligns with its vision of integrating gut microbiome testing into routine healthcare. With partnerships from global leaders like Sonic Healthcare and SYNLAB, Microba is pioneering a $15 billion diagnostic category while advancing microbiome therapeutics targeting a $50 billion market. Notably, its Phase 1 clinical trial has been successfully completed, with Phase 2 preparations underway. The global market opportunity remains vast, particularly in gastrointestinal disease, where 37 million patients annually seek treatment in the US alone. Historically, only half of these patients achieve symptom resolution, underscoring the transformative potential of Microba’s innovations in addressing this unmet need.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.